Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting

Phase 2

Phase 3

BHV-7000Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Sponsor:

Biohaven Therapeutics Ltd.

Code:

NCT06309966

Conditions

Focal Epilepsy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

BHV-7000

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Biohaven Therapeutics Ltd. on 2025-03-26.